Recursion Pharmaceuticals Future Growth
Future criteria checks 2/6
Recursion Pharmaceuticals's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 23% per year. EPS is expected to grow by 10.3% per annum. Return on equity is forecast to be -168.1% in 3 years.
Key information
-1.9%
Earnings growth rate
10.3%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | 23.0% |
| Future return on equity | -168.1% |
| Analyst coverage | Good |
| Last updated | 07 Oct 2024 |
Recent future growth updates
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Recent updates
Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 104 | -380 | -221 | -270 | 5 |
| 12/31/2025 | 63 | -465 | -365 | -337 | 8 |
| 12/31/2024 | 69 | -397 | -311 | -298 | 9 |
| 6/30/2024 | 50 | -375 | -346 | -332 | N/A |
| 3/31/2024 | 46 | -354 | -331 | -317 | N/A |
| 12/31/2023 | 45 | -328 | -300 | -288 | N/A |
| 9/30/2023 | 47 | -293 | -277 | -258 | N/A |
| 6/30/2023 | 50 | -260 | -266 | -240 | N/A |
| 3/31/2023 | 47 | -249 | -273 | -234 | N/A |
| 12/31/2022 | 40 | -239 | -121 | -84 | N/A |
| 9/30/2022 | 29 | -247 | -134 | -100 | N/A |
| 6/30/2022 | 18 | -234 | -113 | -78 | N/A |
| 3/31/2022 | 13 | -212 | -75 | -50 | N/A |
| 12/31/2021 | 10 | -186 | -198 | -159 | N/A |
| 9/30/2021 | 10 | -147 | -129 | -89 | N/A |
| 6/30/2021 | 9 | -124 | -106 | -75 | N/A |
| 3/31/2021 | 6 | -99 | -84 | -58 | N/A |
| 12/31/2020 | 4 | -87 | -52 | -45 | N/A |
| 12/31/2019 | 2 | -62 | -61 | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXRX's revenue (23% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: RXRX's revenue (23% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXRX is forecast to be unprofitable in 3 years.